FRCPath Haem Part 1 MCQ-Oncology 387

A 60yr-old Pt with DLBCL is receiving Pola-RCHP. He develops peripheral neuropathy during treatment. Which property of drug best explains this adverse effect?

• Complement activation on peripheral nerves
• Antibody cross-reactivity with neural antigens
• Inhibition of DNA topoisomerase II
• Disruption of microtubule assembly

See All Options

Want to read more?

Subscribe to hematomorph.com to keep reading this exclusive post.

Subscribe Now